Dyne Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Dyne Therapeutics, Inc. carries a market capitalization of 2.97B, placing it among publicly traded companies globally. Its enterprise value stands at 1.77B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.97B |
| Enterprise Value | 1.77B |
Share Statistics
Dyne Therapeutics, Inc. currently has 165.20M shares outstanding.
| Shares Outstanding | 165.20M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -1.70 |
| P/TBV Ratio | 2.98 |
| P/FCF Ratio | -6.10 |
| P/OCF Ratio | -5.82 |
Financial Position
Dyne Therapeutics, Inc. maintains a current ratio of 19.92, meaning it holds 19.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.50, indicating elevated leverage, while an interest coverage ratio of -45.12 demonstrates limited ability to service its debt obligations.
| Current Ratio | 19.92 |
| Quick Ratio | 18.97 |
| Debt / Equity | 19.50 |
| Debt / EBITDA | -0.36 |
| Interest Coverage | -45.12 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -50.16 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Dyne Therapeutics, Inc.'s stock has gained approximately 35.56895% over the past 52 weeks. The 50-day moving average sits at 18.28, while the 200-day moving average is 17.35.
| Beta (5Y) | N/A |
| 52-Week Price Change | 35.56895% |
| 50-Day Moving Average | 18.28 |
| 200-Day Moving Average | 17.35 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -468.99M, while operating income came in at -471.09M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -471.09M |
| Pretax Income | -451.71M |
| Net Income | -451.71M |
| EBITDA | -468.99M |
| EBIT | -471.09M |
| Earnings Per Share (EPS) | -3.18 |
Balance Sheet
Dyne Therapeutics, Inc. holds 972.16M in cash and equivalents against 168.68M in total debt, resulting in a net debt position of -603.73M. Total book value stands at -1.52B, with working capital of 969.78M providing operational flexibility.
| Cash & Cash Equivalents | 972.16M |
| Total Debt | 168.68M |
| Net Debt | -603.73M |
| Equity (Book Value) | -1.52B |
| Book Value Per Share | -10.68 |
| Working Capital | 969.78M |
Cash Flow
Dyne Therapeutics, Inc. produced -442.24M in operating cash flow over the past twelve months. After subtracting -19.95M in capital expenditures, free cash flow totaled -462.19M - equivalent to -3.25 per share.
| Operating Cash Flow | -442.24M |
| Capital Expenditures | -19.95M |
| Free Cash Flow | -462.19M |
| FCF Per Share | -3.25 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -29.35 |
| FCF Yield | -16.39 |
Scores
Dyne Therapeutics, Inc. posts an Altman Z-Score of 4.86, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.86 |